A Prospective, Randomized Trial to Compare saroGLitazar With pioglitAZone in Nonalcoholic Fatty livEr Disease
Status:
Unknown status
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
Non Alcoholic Fatty Liver Disease (NAFLD) is considered as the component of metabolic
syndrome. The prevalence of the same has been increasing rapidly in India, along with an
increase in the prevalence of diabetes and obesity. Insulin resistance is the key underlying
pathogenetic mechanism of NAFLD. NAFLD accounts for significant morbidity and mortality and
the therapeutic options are limited. Insulin sensitizing drugs are used in the management of
NAFLD.